

PRESS RELEASE

Hansa Biopharma to host Year-end report 2025 conference call

Lund, Sweden, 26 January, 2026. Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), will publish its year-end report for January - December 2025 on Wednesday 11 February, 2026. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CET / 8:00 AM EST. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. During the call, management will review the Company's year-end financial results and provide a business and pipeline update. The presentation will be held in English.

Slides used in the presentation will be made available on the company website at the following link: [Financial reports | Hansa Biopharma](#)

To participate in the telephone conference, please use the dial-in details provided below:

Participant Dial In (USA/Canada Toll Free): 1-833-821-3542

Participant International Dial In: 1-412-652-1248

The webcast will be available on: [Webcast | Hansa Biopharma Fourth Quarter 2025 Earnings](#)

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a focused research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule being developed for the autoimmune disease GBS. Hansa Biopharma is based in Lund, Sweden,

and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on [LinkedIn](#).

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.